Skip to content
Review Open access

Feasibility of EHR-based prescreening for an adjuvant breast cancer trial in a safety-net health system

Aug 2026 · The Oncologist · Vol 31 · 0 citations · 28 references
Medicine

TL;DR

In a safety-net oncology setting, her-assisted prescreening was feasible but required manual verification and clinician involvement, which limited its utility as a standalone screening method.

Abstract

Abstract Introduction Racial and ethnic inequities persist in oncology clinical trial participation, while safety-net health systems may face resource and data limitations that complicate candidate identification. We evaluated the feasibility of an electronic health record (EHR)-assisted prescreening workflow for EMBER-4, a phase 3 adjuvant breast cancer trial, at a safety-net health system. Methods Structured Query Language (SQL) queries applied to Epic Clarity identified potential candidates using diagnosis codes, receptor-status codes, endocrine therapy medication records, recent oncology follow-up, and appointment data. Research staff then manually reviewed pathology reports, treatment history, comorbidities, and other protocol criteria to determine full eligibility. Results The source population with a diagnosis of breast cancer included 829 patients: 29% Hispanic, 30% Black, 31% non-Hispanic White, and 9.7% others. Primary language was English in 75% and Spanish in 18%. The SQL query identified 123 potential candidates; manual review confirmed 18 eligible patients comprising 67% Hispanic and 44% Spanish language, yielding a positive predictive value of 15%. Clinicians identified 3 additional eligible patients missed by the query, for 21 known eligible patients overall. Eleven declined participation, one did not attend the scheduled clinic visit, and 9 consented. One patient withdrew before randomization and 8 were enrolled. Six enrolled patients were Hispanic, 1 was non-Hispanic White and 1 was Black. Conclusions In a safety-net oncology setting, her-assisted prescreening was feasible but required manual verification and clinician involvement. The workflow identified most known eligible patients, although incomplete structured data and low positive predictive value limited its utility as a standalone screening method.

Read PDF

Similar papers

Aug 2026

Rule-Based Identification of a Reliable Real-World Cancer Recurrence Endpoint.

This scalable method enables derivation of real-world endpoints from EHR-based data and may be used to characterize outcomes for patients treated outside of prospective clinical trials and may inform the creation of synthetic control cohorts to support regulatory approvals for new drugs in rare tumor or biomarker defin...

J. Lavery, Samantha Brown, Chelsea Nichols et al. · 0 citations
Review Open access Sep 2026

Healthcare System Drivers of Prostate Cancer Disparities: Real-World Evidence, Informatics Pathways, and Policy Translation

Background: Racial and socioeconomic differences in prostate cancer outcomes are often described as survival disparities, but observed differences may also reflect healthcare access, treatment delivery, and resource allocation. Methods: NCDB and SEER–Medicare were treated as independent, complementary retrospective dat...

Chen Yang, Ze-Lin Guo, Fan Cheng et al. · 0 citations
Sep 2026

Abstract A089: Implementation of an early detection program for pancreatic cancer using electronic health record-based risk prediction models

Early detection remains a major challenge in pancreatic cancer (PC). We evaluated the feasibility of implementing an electronic health record (EHR)-based screening program that uses a validated risk prediction algorithm to identify patients at elevated risk for PC and offer targeted cross-sectional imaging....

T. Luong, Jessica Moore, Qiao-Ling Chen et al. · 0 citations
Sep 2026

Oncology Patients in Clinical Trials: A Health Care Cost Analysis.

OBJECTIVES To assess health care resource utilization and costs among commercially insured patients with colorectal cancer (CRC) or ovarian cancer (OC) participating in clinical trials (PCTs). STUDY DESIGN A retrospective claims analysis from 2017 to 2022 was conducted using the Milliman Consolidated Health Cost Guid...

Christine Ferro, Kate Fitch, Prachi D. Bhatt et al. · 0 citations
Aug 2026

Medicaid Expansion and Overall Mortality in Lung, Breast, and Colorectal Cancer: A Difference-in-Differences Study.

BackgroundMedicaid expansion under the Affordable Care Act (ACA) was designed to improve access to care for low-income adults, but its impact on cancer survival may vary across diseases depending on differences in screening, stage at diagnosis, and treatment pathways.MethodsWe conducted a retrospective cohort study usi...

Oluwasegun A. Akinyemi, J. Heath, Oladayo A. Oyebanji et al. · 0 citations
Sep 2026

Detection Patterns of Breast Cancer Recurrence and Contralateral New Primaries in a Large Integrated Health System.

BACKGROUND Optimizing surveillance for the growing population of breast cancer survivors remains a challenge. Although screening guidelines for initial breast cancer are well established, current surveillance guidelines recommending routine provider examinations rely heavily on expert consensus rather than real-world d...

A. Duffens, Cecile A. Laurent, I. Ergas et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.